Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of adult-onset Rheumatoid Arthritis (RA) of at least 3 months duration but no longer than 15 years~* Subjects with an active adult Rheumatoid Arthritis disease~* Subjects who have been on Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy for at least 12 weeks~Exclusion Criteria:~* Subject must not have a secondary, non-inflammatory type of musculoskeletal condition (eg, osteoarthritis or fibromyalgia) that in the investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of Rheumatoid Arthritis (RA)~* Subject must not have a diagnosis of any other inflammatory arthritis (eg, psoriatic arthritis or ankylosing spondylitis)~* Subject must not have a history of an infected joint prosthesis at any time with prosthesis still in situ~* Subject must not have received more than 1 biological agent~* Subject must not have a history of lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time~* Subject with known Tuberculosis (TB) disease, high risk of acquiring TB infection or latent TB infection~* Subject must not have a known hypersensitivity to any components of the investigational medicinal product~* Subject must not have contraindications for Magnetic Resonance Image (MRI) and contrast agent~* Subject must not have any other condition which, in the investigator's judgement, would make them unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo followed by Certolizumab Pegol (CZP) (Type: OTHER): Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
- Certolizumab Pegol (CZP) (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40

Based on this trial design, predict the completion outcome and termination type (if applicable).